# Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients

> **NCT01927224** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 37 (actual)

## Conditions studied

- Chagas Disease

## Interventions

- **DRUG:** Nifurtimox (BAYa2502) (4 x 30 mg tablet)
- **DRUG:** Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)
- **DRUG:** Nifurtimox (BAYa2502) (120 mg tablet)

## Key facts

- **NCT ID:** NCT01927224
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-05
- **Final completion:** 2014-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01927224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01927224, "Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01927224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*